Form 4: CalciMedica Director Frederic Guerard Granted 40,000 Stock Options

CalciMedica, Inc. (CALC) has reported that Director Frederic Guerard was granted 40,000 stock options following stockholder approval of an amended equity incentive plan.

Summary

• Frederic Guerard, a Director of CalciMedica, Inc. (CALC), was granted a total of 40,000 Director Stock Options on June 24, 2025.
• These options were approved by the Board of Directors on April 23, 2025, contingent on stockholder approval of an amendment to the Company's 2023 Equity Incentive Plan (the 'Amended 2023 EIP'), which was obtained on June 24, 2025.
• The granted options include 30,000 shares with an exercise price of $1.53 per share and 10,000 shares with an exercise price of $1.65 per share.
• Vesting schedules vary for the different tranches of options:
• 10,000 shares vest in equal monthly installments over a one-year period following March 26, 2025.
• 5,000 shares are immediately exercisable.
• 15,000 shares vest in equal monthly installments over a one-year period following April 1, 2025.
• 10,000 shares vest in equal monthly installments over a one-year period following June 24, 2025, with full vesting guaranteed by the date of the Company's 2026 annual meeting of stockholders.
• All options have an expiration date of either April 22, 2035 (for 30,000 shares) or June 23, 2035 (for 10,000 shares).

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard practice for incentivizing long-term performance and aligning management interests with shareholders. While it introduces potential future dilution, it's a routine compensation event and generally viewed as a positive for governance and alignment.

Positives

• The grant of stock options to a director helps align their long-term interests with those of the shareholders, incentivizing performance and value creation.
• Stockholder approval of the Amended 2023 Equity Incentive Plan demonstrates a commitment to corporate governance and transparency in executive and director compensation.

Negatives

• The issuance of new stock options introduces potential future dilution for existing shareholders if and when these options are exercised.

Risks

• Potential future dilution of existing shareholder equity upon the exercise of the granted stock options.

Future Outlook

The vesting schedules for the granted options indicate a future stream of equity compensation becoming exercisable, which is designed to align the director's long-term incentives with the company's future performance and shareholder value creation.

Management Comments

• "The option grant was approved by the Board of Directors of CalciMedica, Inc. (the 'Company') on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the 'Amended 2023 EIP') under which the option was granted."
• "The Company's stockholders approved the Amended 2023 EIP on June 24, 2025."

Industry Context

This Form 4 filing reports a routine insider transaction, specifically the grant of stock options to a director. Such equity grants are a common practice across publicly traded companies in various industries, serving as a key component of compensation packages designed to attract, retain, and incentivize key personnel by aligning their financial interests with the long-term success of the company.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution if the options are exercised, but also benefit from improved alignment of the director's interests with long-term shareholder value.
• Director (Frederic Guerard): Receives equity-based compensation, incentivizing continued service and performance tied to the company's stock price.

Next Steps

• Continued vesting of the granted stock options according to their respective schedules, with portions vesting monthly over a one-year period from various start dates.
• The Company's 2026 annual meeting of stockholders, by which time a portion of the options will be fully vested.

Key Dates

Keywords

CalciMedica, CALC, Form 4, Stock Options, Director Compensation, Equity Incentive Plan, Insider Transaction, Corporate Governance